Drug Search Results
More Filters [+]

Noscapine

Alternative Names: noscapine
Latest Update: 2024-06-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: S1R Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Chile | Egypt | France | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Lebanon | Luxembourg | Malaysia | Netherlands | Norway | Pakistan | Peru | Russia | Saudi Arabia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine

Approved Indications: None

Known Adverse Events: None

Company: INFECTOPHARM Arzneimittel und Consilium
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Noscapine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Healthy Volunteers

Phase 2: Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia

Phase 1: Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2019-002012-12

P4

Active, not recruiting

Healthy Volunteers

2021-12-06

2014-003151-62

P4

Terminated

Healthy Volunteers

2015-01-30

COU-NOS-001

P1

Terminated

Multiple Myeloma

2010-07-01

0C-99-16

P2

Terminated

Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin

2006-12-01

Recent News Events